{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T03:07:56Z","timestamp":1781579276862,"version":"3.54.5"},"reference-count":40,"publisher":"European Respiratory Society (ERS)","issue":"1","license":[{"start":{"date-parts":[[2020,12,10]],"date-time":"2020-12-10T00:00:00Z","timestamp":1607558400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["publications.ersnet.org"],"crossmark-restriction":true},"short-container-title":["ERJ Open Res"],"accepted":{"date-parts":[[2020,11,23]]},"published-print":{"date-parts":[[2021,1]]},"abstract":"<jats:p>Cough is induced by inhaled prostacyclin analogues including treprostinil (TRE), and, at higher doses, treprostinil palmitil (TP), a prodrug of TRE. In this report, we have investigated mechanisms involved in TRE- and TP-induced cough, using a dry powder formulation of TP (TPIP) to supplement previous data obtained with an aqueous suspension formulation of TP (TPIS).<\/jats:p><jats:p>Experiments in guinea pigs and rats investigated the prostanoid receptor subtype producing cough and whether it involved activation of sensory nerves in the airways and vasculature. Experiments involved treatment with prostanoid, tachykinin and bradykinin receptor antagonists, a cyclooxygenase inhibitor and TRE administration to the isolated larynx or intravenously.<\/jats:p><jats:p>In guinea pigs, cough with inhaled TRE (1.23\u2005\u00b5g\u00b7kg<jats:sup>\u22121<\/jats:sup>) was not observed with an equivalent dose of TPIP and required higher inhaled doses (12.8 and 35.8\u2005\u00b5g\u00b7kg<jats:sup>\u22121<\/jats:sup>) to induce cough. TRE cough was blocked with IP and tachykinin NK<jats:sub>1<\/jats:sub>receptor antagonists but not with EP<jats:sub>1<\/jats:sub>, EP<jats:sub>2<\/jats:sub>, EP<jats:sub>3<\/jats:sub>, DP<jats:sub>1<\/jats:sub>or bradykinin B<jats:sub>2<\/jats:sub>antagonists or a cyclooxygenase inhibitor. TRE administered to the isolated larynx or intravenously in rats produced no apnoea or swallowing, whereas citric acid, capsaicin and hypertonic saline had significant effects.<\/jats:p><jats:p>The mechanisms inducing cough with inhaled TRE likely involves the activation of prostanoid IP receptors on jugular C-fibres in the tracheobronchial airways. Cough induced by inhaled dry powder and nebulised formulations of TP occurs at higher inhaled doses than TRE, presumably due to the slow, sustained release of TRE from the prodrug resulting in lower concentrations of TRE at the airway sensory nerves.<\/jats:p>","DOI":"10.1183\/23120541.00592-2020","type":"journal-article","created":{"date-parts":[[2020,12,10]],"date-time":"2020-12-10T19:32:04Z","timestamp":1607628724000},"page":"00592-2020","update-policy":"https:\/\/doi.org\/10.1183\/ers-crossmark-policy","source":"Crossref","is-referenced-by-count":12,"title":["Characterisation of cough evoked by inhaled treprostinil and treprostinil palmitil"],"prefix":"10.1183","volume":"7","author":[{"given":"Richard W.","family":"Chapman","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michel R.","family":"Corboz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlos","family":"Fernandez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eugene","family":"Sullivan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andy","family":"Stautberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adam J.","family":"Plaunt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Donna M.","family":"Konicek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vladimir","family":"Malinin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhili","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Cipolla","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Walter","family":"Perkins","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"81","published-online":{"date-parts":[[2020,12,10]]},"reference":[{"key":"2024101711001756000_7.1.00592-2020.1","doi-asserted-by":"publisher","DOI":"10.1124\/jpet.117.242446"},{"key":"2024101711001756000_7.1.00592-2020.2","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1016\/j.pupt.2018.02.002","article-title":"Inhaled hexadecyl-treprostinil provides pulmonary vasodilator activity at significantly lower plasma concentrations than infused treprostinil","volume":"49","author":"Chapman","year":"2018","journal-title":"Pulm Pharmacol Ther"},{"key":"2024101711001756000_7.1.00592-2020.3","unstructured":"Tyvaso\u00ae (treprostinil) [package insert] (2014). Research Triangle Park, NC, USA; United Therapeutics Corporation."},{"key":"2024101711001756000_7.1.00592-2020.4","doi-asserted-by":"crossref","first-page":"19","DOI":"10.2147\/DDDT.S19281","article-title":"Inhaled treprostinil: a therapeutic review","volume":"6","author":"Channick","year":"2012","journal-title":"Drug Design Dev Ther"},{"key":"2024101711001756000_7.1.00592-2020.5","doi-asserted-by":"crossref","first-page":"535","DOI":"10.2147\/TCRM.S75122","article-title":"Prostanoid therapies in the management of pulmonary arterial hypertension","volume":"11","author":"LeVarge","year":"2015","journal-title":"Ther Clin Risk Manag"},{"key":"2024101711001756000_7.1.00592-2020.6","doi-asserted-by":"publisher","DOI":"10.1124\/pr.111.005587"},{"key":"2024101711001756000_7.1.00592-2020.7","first-page":"PA2398","article-title":"Single dose pharmacokinetics of C16TR for inhalation (INS1009) vs treprostinil inhalation solution (Tyvaso\u00ae)","volume":"48","author":"Han","year":"2016","journal-title":"Eur Respir J"},{"key":"2024101711001756000_7.1.00592-2020.8","first-page":"PA2403","article-title":"Safety and pharmacokinetics of a single ascending dose of C16TR for inhalation (INS1009)","volume":"48","author":"Han","year":"2016","journal-title":"Eur Respir J"},{"key":"2024101711001756000_7.1.00592-2020.9","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.congress-2018.PA3048"},{"key":"2024101711001756000_7.1.00592-2020.10","first-page":"A5613","article-title":"Determination of the prostanoid receptor subtype involved in treprostinil-induced cough in guinea pigs","volume":"201","author":"Corboz","year":"2020","journal-title":"Am J Respir Crit Care Med"},{"key":"2024101711001756000_7.1.00592-2020.11","unstructured":"Li Z , Bhamidipati M , Gauani H , et al. Comparison of dry powder inhaler devices for use with a long acting pulmonary vasodilator, DP-INS1009. Poster presented at Respiratory Drug Delivery (RDD) Europe 2017, 25\u201328 April, 2017, Antibes, France."},{"key":"2024101711001756000_7.1.00592-2020.12","doi-asserted-by":"publisher","DOI":"10.1080\/08958370802207318"},{"key":"2024101711001756000_7.1.00592-2020.13","doi-asserted-by":"publisher","DOI":"10.1183\/09031936.00101006"},{"key":"2024101711001756000_7.1.00592-2020.14","doi-asserted-by":"publisher","DOI":"10.1111\/j.1476-5381.2009.00317.x"},{"key":"2024101711001756000_7.1.00592-2020.15","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01920-17"},{"key":"2024101711001756000_7.1.00592-2020.16","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1016\/j.pupt.2017.09.003","article-title":"Role of prostaglandin E2 in bronchoconstriction-triggered cough responses in guinea pigs","volume":"48","author":"Okazaki","year":"2018","journal-title":"Pulm Pharmacol Therap"},{"key":"2024101711001756000_7.1.00592-2020.17","doi-asserted-by":"publisher","DOI":"10.1124\/jpet.115.230383"},{"key":"2024101711001756000_7.1.00592-2020.18","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1152\/jappl.1997.83.3.723","article-title":"Reflex apneic response evoked by laryngeal exposure to wood smoke in rats: neural and chemical mechanisms","volume":"83","author":"Lin","year":"1997","journal-title":"J Appl Physiol"},{"key":"2024101711001756000_7.1.00592-2020.19","doi-asserted-by":"publisher","DOI":"10.1152\/japplphysiol.00064.2006"},{"key":"2024101711001756000_7.1.00592-2020.20","doi-asserted-by":"crossref","first-page":"4667","DOI":"10.1113\/jphysiol.2013.256024","article-title":"Laryngeal and tracheal afferent nerve stimulation evokes swallowing in anesthetized guinea pigs","volume":"18","author":"Tsujimura","year":"2013","journal-title":"J Physiol"},{"key":"2024101711001756000_7.1.00592-2020.21","doi-asserted-by":"publisher","DOI":"10.1152\/japplphysiol.01101.2005"},{"key":"2024101711001756000_7.1.00592-2020.22","doi-asserted-by":"publisher","DOI":"10.1007\/s00408-009-9190-2"},{"key":"2024101711001756000_7.1.00592-2020.23","doi-asserted-by":"crossref","first-page":"3976","DOI":"10.1111\/bph.14472","article-title":"Efficacy of treprostinil in the SU5416-hypoxia model of severe pulmonary arterial hypertension: hemodynamic benefits are not associated with improvements in arterial remodelling","volume":"175","author":"Chaudhary","year":"2018","journal-title":"Br J Pharmacol"},{"issue":"Suppl. 1","key":"2024101711001756000_7.1.00592-2020.24","doi-asserted-by":"crossref","first-page":"S23","DOI":"10.1007\/s00408-007-9054-6","article-title":"The cough reflex in animals: relevance to human cough research","volume":"186","author":"Canning","year":"2008","journal-title":"Lung"},{"key":"2024101711001756000_7.1.00592-2020.25","doi-asserted-by":"crossref","first-page":"1364","DOI":"10.1164\/rccm.201508-1602OC","article-title":"Neurophenotypes in airway disease. Insights from translational cough studies","volume":"193","author":"Belvisi","year":"2016","journal-title":"Am J Respir Crit Care Med"},{"key":"2024101711001756000_7.1.00592-2020.26","doi-asserted-by":"publisher","DOI":"10.1016\/j.bcp.2012.03.012"},{"key":"2024101711001756000_7.1.00592-2020.27","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.200903-0388OC"},{"key":"2024101711001756000_7.1.00592-2020.28","doi-asserted-by":"publisher","DOI":"10.1183\/09031936.00061614"},{"key":"2024101711001756000_7.1.00592-2020.29","doi-asserted-by":"crossref","first-page":"1823","DOI":"10.1152\/jappl.1985.58.6.1823","article-title":"Reflex tracheal contraction evoked in dogs by bronchodilator prostaglandins E2 and I2","volume":"58","author":"Roberts","year":"1985","journal-title":"J Appl Physiol"},{"key":"2024101711001756000_7.1.00592-2020.30","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1111\/j.1476-5381.1991.tb12383.x","article-title":"Prostacyclin activates tachykinin release from capsaicin-sensitive afferents in guinea pig bronchi through a ruthenium red-sensitive pathway","volume":"104","author":"Mapp","year":"1991","journal-title":"Br J Pharmacol"},{"key":"2024101711001756000_7.1.00592-2020.31","doi-asserted-by":"publisher","DOI":"10.1124\/jpet.105.091967"},{"key":"2024101711001756000_7.1.00592-2020.32","doi-asserted-by":"publisher","DOI":"10.1186\/1745-9974-3-2"},{"key":"2024101711001756000_7.1.00592-2020.33","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bjp.0703090"},{"key":"2024101711001756000_7.1.00592-2020.34","first-page":"472","article-title":"Pharmacology of CP-99,994: a nonpeptide antagonist of the tachykinin neurokinin-1 receptor","volume":"267","author":"McLean","year":"1993","journal-title":"J Pharmacol Exp Ther"},{"key":"2024101711001756000_7.1.00592-2020.35","doi-asserted-by":"publisher","DOI":"10.1152\/physrev.00039.2015"},{"key":"2024101711001756000_7.1.00592-2020.36","doi-asserted-by":"publisher","DOI":"10.1152\/ajpregu.00313.2017"},{"key":"2024101711001756000_7.1.00592-2020.37","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1111\/j.1476-5381.1995.tb16334.x","article-title":"Inhibition of rat colon contractility by prostacyclin (IP-) receptor agonists: involvement of NANC neurotransmission","volume":"115","author":"Qian","year":"1995","journal-title":"Br J Pharmacol"},{"key":"2024101711001756000_7.1.00592-2020.38","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.00294-2018"},{"key":"2024101711001756000_7.1.00592-2020.39","doi-asserted-by":"publisher","DOI":"10.1111\/j.1749-6632.2011.05961.x"},{"key":"2024101711001756000_7.1.00592-2020.40","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1016\/j.chest.2019.08.001","article-title":"The neurokinin-1 receptor antagonist Orvepitant is a novel antitussive therapy for chronic refractory cough","volume":"157","author":"Smith","year":"2020","journal-title":"Chest"}],"container-title":["ERJ Open Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1183\/23120541.00592-2020","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,24]],"date-time":"2025-02-24T05:05:36Z","timestamp":1740373536000},"score":1,"resource":{"primary":{"URL":"https:\/\/publications.ersnet.org\/lookup\/doi\/10.1183\/23120541.00592-2020"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,12,10]]},"references-count":40,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2021,2,15]]},"published-print":{"date-parts":[[2021,1]]}},"alternative-id":["10.1183\/23120541.00592-2020"],"URL":"https:\/\/doi.org\/10.1183\/23120541.00592-2020","relation":{},"ISSN":["2312-0541"],"issn-type":[{"value":"2312-0541","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,12,10]]}}}